From:
`To:
`Cc:
`Subject:
`Date:
`Attachments:
`
`Trials
`Deborah Sterling; Trials
`Eric Stops; Nick Cerrito; John Galanek; Frank Calvosa; Daniel Wiesner; Olga A. Partington
`RE: PGR2019-00048 - request for conference call
`Thursday, September 12, 2019 1:27:51 PM
`image001.png
`image002.png
`
`Counsel:
`Petitioner is authorized to file to file a 3-page Reply to Corcept’s Preliminary Patent Owner Response
`(“POPR”) to address statements in Corcept’s POPR regarding the schedule of the concurrent litigation
`involving the ’214 patent. Petitioner’s Reply shall be filed on or before September 23, 2019. Patent Owner
`is authorized to file a Sur-Reply to Petitioner’s Reply. Patent Owner’s Sur-Reply shall be filed on or before
`October 3, 2019. We will issue an order to this effect in due course.
`
`Regards,
`
`Andrew Kellogg,
`Supervisory Paralegal
`Patent Trial and Appeal Board
`USPTO
`andrew.kellogg@uspto.gov
`Direct: 571-272-5366
`
`From: Deborah Sterling <DSTERLING@sternekessler.com>
`Sent: Wednesday, September 11, 2019 10:32 AM
`To: Trials <Trials@USPTO.GOV>
`Cc: Eric Stops <ericstops@quinnemanuel.com>; Nick Cerrito <nickcerrito@quinnemanuel.com>;
`John Galanek <johngalanek@quinnemanuel.com>; Frank Calvosa
`<frankcalvosa@quinnemanuel.com>; Daniel Wiesner <danielwiesner@quinnemanuel.com>; Olga A.
`Partington <OPARTINGTON@sternekessler.com>
`Subject: PGR2019-00048 - request for conference call
`
`Dear Board,
`
` I
`
` write on behalf of Petitioner Teva Pharmaceuticals USA, Inc. to respectfully request a conference
`call with the Board in PGR2019-00048. Teva wishes to request authorization to file a 3-page reply to
`Corcept’s Preliminary Patent Owner Response to address certain statements in Corcept’s POPR that
`mischaracterize the schedule of the concurrent litigation involving the ’214 patent.
`
`The parties have met and conferred and counsel for Corcept has advised that Corcept will not
`oppose Teva’s request for a reply if Teva does not oppose a request from Corcept to file a 3-page
`sur-reply. Teva has agreed to not oppose a sur-reply if Teva is authorized to file a reply.
`
`The parties are available for a call at the Board’s convenience between 10 am – 5 pm Eastern time
`on September 12 or 13, to address why good cause exists.
`
`Respectfully submitted,
`
`

`

`Deborah Sterling (Counsel for Petitioner)
`
`Deborah Sterling, Ph.D.
`Director
`Sterne, Kessler, Goldstein & Fox P.L.L.C.
`1100 New York Avenue, NW, Washington, DC 20005
`Email: dsterling@sternekessler.com
`Direct: 202.772.8501
`
`IP Assistant: Katherine Valencia
`Direct: 202.772.8937 Main: 202.371.2600
`
`Notice: The information in this electronic transmission (including any attachments) may contain confidential
`or legally privileged information and is intended solely for the individual(s) or entity(ies) named above. If you
`are not an intended recipient or an authorized agent, you are hereby notified that reading, distributing, or
`otherwise disseminating or copying, or taking any action based on the contents of this transmission is strictly
`prohibited. Any unauthorized interception of this transmission is illegal under the law. If you have received
`this transmission in error, please immediately notify the sender by return email and then destroy all copies of
`the transmission.
`
`